Cargando…

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication

Type B adverse drug reactions (ADRs) are unpredictable based on the drug’s pharmacology and represent a key challenge in pharmacovigilance. For human leukocyte antigen (HLA)-mediated type B ADRs, it is assumed that the protein/small-molecule interaction alters the biophysical and mechanistic propert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haukamp, Funmilola Josephine, Gall, Eline, Hò, Gia-Gia Toni, Hiemisch, Wiebke, Stieglitz, Florian, Kuhn, Joachim, Blasczyk, Rainer, Pich, Andreas, Bade-Döding, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781935/ https://www.ncbi.nlm.nih.gov/pubmed/35055355 http://dx.doi.org/10.3390/jpm12010040

Ejemplares similares

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects
por: Gall, Eline, et al.
Publicado: (2022)

HLA-B*57:01/Carbamazepine-10,11-Epoxide Association Triggers Upregulation of the NFκB and JAK/STAT Pathways
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2023)

HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
por: Hò, Gia-Gia T., et al.
Publicado: (2019)

The Loss of HLA-F/KIR3DS1 Ligation Is Mediated by Hemoglobin Peptides
por: Hò, Gia-Gia T., et al.
Publicado: (2020)

HLA-F Allele-Specific Peptide Restriction Represents an Exceptional Proteomic Footprint
por: Hò, Gia-Gia T., et al.
Publicado: (2019)

HLA-G peptide preferences change in transformed cells: impact on the binding motif
por: Celik, Alexander A., et al.
Publicado: (2018)

NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain
por: Hò, Gia-Gia T., et al.
Publicado: (2020)

Carbamazepine-Mediated Adverse Drug Reactions: CBZ-10,11-epoxide but Not Carbamazepine Induces the Alteration of Peptides Presented by HLA-B∗15:02
por: Simper, Gwendolin S., et al.
Publicado: (2018)

The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity
por: Simper, Gwendolin S., et al.
Publicado: (2019)

Between Innate and Adaptive Immune Responses: NKG2A, NKG2C, and CD8(+) T Cell Recognition of HLA-E Restricted Self-Peptides Acquired in the Absence of HLA-Ia
por: Pump, Wiebke C., et al.
Publicado: (2019)

The microstructure in the placenta is influenced by the functional diversity of HLA-G allelic variants
por: Stieglitz, F., et al.
Publicado: (2019)

The polymorphism at residue 156 determines the HLA-B*35 restricted peptide repertoire during HCMV infection
por: Abels, Wiebke C., et al.
Publicado: (2018)

Releasing the concept of HLA‐allele specific peptide anchors in viral infections: A non‐canonical naturally presented human cytomegalovirus‐derived HLA‐A*24:02 restricted peptide drives exquisite immunogenicity
por: Pump, Wiebke C., et al.
Publicado: (2019)

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care
por: De Spiegelaere, Ward, et al.
Publicado: (2015)

Soluble HLA-G and HLA-G Bearing Extracellular Vesicles Affect ILT-2 Positive and ILT-2 Negative CD8 T Cells Complementary
por: Schwich, Esther, et al.
Publicado: (2020)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors
por: Sooda, Anuradha, et al.
Publicado: (2022)

The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch
por: Celik, Alexander A., et al.
Publicado: (2015)

Battle between Host Immune Cellular Responses and HCMV Immune Evasion
por: Manandhar, Trishna, et al.
Publicado: (2019)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA(®) observational database: a cohort study
por: Mounzer, Karam, et al.
Publicado: (2019)

HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response—Implications on HSCT Outcome
por: Kraemer, Thomas, et al.
Publicado: (2015)

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

Rapid Detection of HLA-B*57:01-Expressing Cells Using a Label-Free Interdigitated Electrode Biosensor Platform for Prevention of Abacavir Hypersensitivity in HIV Treatment
por: Chan, Jianxiong, et al.
Publicado: (2019)

Soluble HLA Technology as a Strategy to Evaluate the Impact of HLA Mismatches
por: Kunze-Schumacher, Heike, et al.
Publicado: (2014)

HLA-E: A Novel Player for Histocompatibility
por: Kraemer, Thomas, et al.
Publicado: (2014)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno
por: Senatore, C, et al.
Publicado: (2014)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1
por: O'Connor, Geraldine M., et al.
Publicado: (2015)

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
por: Puig, Montserrat, et al.
Publicado: (2021)

Rapid HIV disease progression following superinfection in an HLA-B*27:05/B*57:01-positive transmission recipient
por: Brener, Jacqui, et al.
Publicado: (2018)

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01
por: Cascella, R, et al.
Publicado: (2015)

Influence of Glycosylation Inhibition on the Binding of KIR3DL1 to HLA-B*57:01
por: Salzberger, Wilhelm, et al.
Publicado: (2015)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity
por: Metushi, Imir G., et al.
Publicado: (2015)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
por: Martínez Buitrago, Ernesto, et al.
Publicado: (2019)

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
por: Kolou, Malewe, et al.
Publicado: (2021)

Abacavir forms novel cross-linking abacavir protein adducts in patients
por: Meng, Xiaoli, et al.
Publicado: (2014)

CCM no. 80-01: no. 57
Publicado: (1980)

Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes
por: Manandhar, Trishna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mpeihm45bhch470buj19l7453h